| Literature DB >> 28446552 |
Ildiko Horváth1, Peter J Barnes2, Stelios Loukides3, Peter J Sterk4, Marieann Högman5, Anna-Carin Olin6, Anton Amann7, Balazs Antus8, Eugenio Baraldi9, Andras Bikov10, Agnes W Boots11, Lieuwe D Bos12, Paul Brinkman4, Caterina Bucca13, Giovanna E Carpagnano14, Massimo Corradi15, Simona Cristescu16, Johan C de Jongste17, Anh-Tuan Dinh-Xuan18, Edward Dompeling19, Niki Fens4, Stephen Fowler20, Jens M Hohlfeld21,22, Olaf Holz21, Quirijn Jöbsis23, Kim Van De Kant19, Hugo H Knobel24, Konstantinos Kostikas25, Lauri Lehtimäki26, Jon Lundberg27, Paolo Montuschi28, Alain Van Muylem29, Giorgio Pennazza30, Petra Reinhold31, Fabio L M Ricciardolo32, Philippe Rosias19,33, Marco Santonico30, Marc P van der Schee4, Frederik-Jan van Schooten11, Antonio Spanevello34, Thomy Tonia35, Teunis J Vink24.
Abstract
Breath tests cover the fraction of nitric oxide in expired gas (FeNO), volatile organic compounds (VOCs), variables in exhaled breath condensate (EBC) and other measurements. For EBC and for FeNO, official recommendations for standardised procedures are more than 10 years old and there is none for exhaled VOCs and particles. The aim of this document is to provide technical standards and recommendations for sample collection and analytic approaches and to highlight future research priorities in the field. For EBC and FeNO, new developments and advances in technology have been evaluated in the current document. This report is not intended to provide clinical guidance on disease diagnosis and management.Clinicians and researchers with expertise in exhaled biomarkers were invited to participate. Published studies regarding methodology of breath tests were selected, discussed and evaluated in a consensus-based manner by the Task Force members.Recommendations for standardisation of sampling, analysing and reporting of data and suggestions for research to cover gaps in the evidence have been created and summarised.Application of breath biomarker measurement in a standardised manner will provide comparable results, thereby facilitating the potential use of these biomarkers in clinical practice.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28446552 DOI: 10.1183/13993003.00965-2016
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671